Today: 19 May 2026
Browse Category

Biotechnology 23 January 2026 - 5 February 2026

TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

TransCode Therapeutics shares surged nearly 19% Thursday after the company filed an amended IND application for a Phase 2a trial of TTX-MC138 in colorectal cancer patients. Trading volume hit 11.5 million shares, up from 8,500 the previous day. The dose-expansion study, set to begin in early 2026, will enroll up to 45 patients with positive ctDNA markers. The trial will run with Quantum Leap Healthcare Collaborative on the PRE-I-SPY platform.
5 February 2026
·
Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen shares surged 8.2% to $366.20 Wednesday after quarterly earnings beat forecasts and the company issued a 2026 outlook above consensus. Investors focused on progress in Amgen’s MariTide obesity program, which could allow less frequent dosing. The company reported Q4 revenue of $9.9 billion and adjusted EPS of $5.29. Amgen plans $2.6 billion in 2026 capital spending and capped share buybacks at $3 billion.
5 February 2026
···
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott Laboratories shares edged up 0.1% to $109.43 after Barclays cut its price target to $142 but kept an Overweight rating. Nutrition sales fell 8.9% last quarter, and diagnostics dropped 2.5%. Exact Sciences shareholders will vote February 20 on Abbott’s planned $23 billion takeover. The deal is expected to close in the second quarter of 2026.
2 February 2026
···
Twist Bioscience stock jumps as record quarterly revenue lifts 2026 outlook — what investors watch next

Twist Bioscience stock jumps as record quarterly revenue lifts 2026 outlook — what investors watch next

Twist Bioscience shares surged 14% to $46.88 Monday after posting record Q1 revenue of $103.7 million and raising its full-year forecast. Gross margin reached 52%, with net loss narrowing to $30.5 million. The company reaffirmed its target to reach adjusted EBITDA breakeven by late fiscal 2026. Investors are watching if Twist can sustain margins and meet its March-quarter revenue guidance.
2 February 2026
···
Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen shares fell 0.3% to $341.88 Friday after disclosing plans to end its 2021 partnership with Kyowa Kirin, which will regain global rights to the eczema drug rocatinlimab. Amgen will report fourth-quarter and full-year earnings after markets close Feb. 3, with investors focused on pipeline priorities following the Kyowa Kirin exit.
31 January 2026
····
Thermo Fisher stock slides on 2026 profit outlook as research funding cuts bite — what’s next for TMO

Thermo Fisher stock slides on 2026 profit outlook as research funding cuts bite — what’s next for TMO

Thermo Fisher shares fell 2.6% to $592.16 after the company forecast 2026 profits below Wall Street estimates, citing weaker U.S. academic research funding. The company projected adjusted earnings of $24.22 to $24.80 per share, missing consensus. Fourth-quarter revenue rose 7% to $12.21 billion, beating expectations. CFO Stephen Williamson will retire in March, with Jim Meyer named as successor.
30 January 2026
··
Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics shares rose 3.7% to $21.62 Thursday after the FDA halted Regenxbio’s gene therapy trials over a brain tumor case, intensifying focus on Denali’s Hunter syndrome drug under FDA review. Investors await Denali’s clinical data update in early February and a regulatory decision by April 5. The iShares Nasdaq Biotechnology ETF was little changed.
29 January 2026
····
Thermo Fisher (TMO) stock slides into earnings — here’s what Wall Street is watching

Thermo Fisher (TMO) stock slides into earnings — here’s what Wall Street is watching

Thermo Fisher shares fell 2.55% to $608.02 Wednesday, their second straight decline ahead of Thursday’s Q4 earnings call. Trading volume topped 2.3 million, above average, as investors weighed Danaher’s warning on weak academic research funding. The stock now sits 5.6% below its Jan. 22 high. Life-science tools stocks broadly declined during the session.
29 January 2026
···
Gilead (GILD) stock hits fresh 52-week high as new analyst targets and CEO sale filing land

Gilead (GILD) stock hits fresh 52-week high as new analyst targets and CEO sale filing land

Gilead Sciences shares closed at a 52-week high of $137.78 on Monday, up 1.36% for a fourth straight gain. CEO Daniel O’Day sold $15.6 million in stock under a pre-set plan, according to an SEC filing. BMO and UBS raised their price targets, citing momentum in HIV drugs and new coverage for Yeztugo. Trading volume exceeded normal levels as the stock outperformed major pharma peers.
27 January 2026
··
Thermo Fisher Scientific stock rises toward $631 as TMO heads into Jan. 29 earnings

Thermo Fisher Scientific stock rises toward $631 as TMO heads into Jan. 29 earnings

Thermo Fisher shares rose 0.8% to $631.24 by midday Monday in New York, rebounding from an early dip ahead of Thursday’s earnings report and 2026 outlook. Options markets point to an expected 4% swing after results. Analysts forecast Q4 earnings of $6.43 per share, up from $6.10 a year ago. The company will hold its earnings call at 8:30 a.m. ET on Jan. 29.
26 January 2026
··
Voyager Technologies stock jumps again on ISS drug-discovery deal, Wedbush call — what to watch next

Voyager Technologies stock jumps again on ISS drug-discovery deal, Wedbush call — what to watch next

Voyager Technologies shares closed up 7.4% at $37.09 Friday after announcing a contract with Space LiinTech for a microgravity drug research payload to the ISS. Wedbush initiated coverage with an Outperform rating and $46 target. Liberty Street Advisors disclosed a $17.8 million stake as of Dec. 31. Investors await updates at February conference appearances.
25 January 2026
·
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·····
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.
23 January 2026
·····
1 2 3 4 5 … 17

Stock Market Today

  • 5 TSX Dividend Stocks Yielding 3% to 5% for Reliable Cash Flow
    May 18, 2026, 10:18 PM EDT. Building a portfolio of TSX dividend stocks can deliver steady income and market resilience. Top picks include Enbridge (TSX:ENB), an energy infrastructure giant offering a 5.1% yield backed by decades of consistent dividend growth. RioCan REIT (TSX:REI.UN) provides a unique monthly dividend of 5.4%, combining commercial real estate and residential exposure in Canadian metros. Toronto-Dominion Bank (TSX:TD) stands out among big banks with a 2.9% yield, nearly two centuries of dividends, and strong U.S. growth. These selections cover varied sectors and offer investors dependable cash flow with defensive qualities amid market volatility.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Dominion Energy Shares Move After NextEra’s $67 Billion Plan Seen as AI Power Play

Dominion Energy Shares Move After NextEra’s $67 Billion Plan Seen as AI Power Play

19 May 2026
NextEra Energy agreed to acquire Dominion Energy in a $66.8 billion all-stock deal, sending Dominion shares up 9.4% to $67.56 while NextEra fell 4.6%. Dominion holders would get 0.8138 NextEra share per Dominion share and a $360 million cash payment. The deal requires multiple regulatory approvals. Dominion’s Coastal Virginia Offshore Wind project remains a focus after cutting costs to $11.4 billion.
Go toTop